Testing a new method to detect COVID-19 using exhaled air
Official title: Evaluation of Concordance Between an Innovative Test on Exhaled Air (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2 in Symptomatic Patients or Closed Contacts
Run by Centre Hospitalier Universitaire de Nīmes · NCT06099795 · Data updated 2026-11-12
This study is testing a new breath test for COVID-19 to see if it works as well as the traditional nose swab method, especially for people showing symptoms or who have been around someone infected.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nīmes Academic / other |
| Locations | 2 sites (Nîmes and 1 other locations) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | May 27, 2026 |
| Trial ID | NCT06099795 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 years old who are suspected of having COVID-19, either due to symptoms or close contact with an infected person.
✕Probably not a fit
Patients who are unable to understand the testing procedures or are currently participating in another interventional study may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of the eBAM-CoV test, which detects SARS-CoV-2 viral proteins in exhaled air, compared to the traditional RT-PCR method that uses nasopharyngeal swabs. The eBAM-CoV test aims to provide a less invasive and more immediate assessment of viral load, particularly in symptomatic patients or those who have been in close contact with infected individuals. Researchers will analyze the concordance between the two testing methods to determine the reliability of the eBAM-CoV test for COVID-19 diagnosis.
Why it matters
Potential benefit: If successful, this test could offer a quicker and less invasive way to diagnose COVID-19, improving patient care and response times.
How similar studies have gone: While traditional RT-PCR testing has been widely used, the eBAM-CoV test represents a novel approach that has not been extensively tested in similar studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult male or female patients over 18 years of age (≥) * Suspected of being infected with COVID-19 (symptomatic or contact case) and consulting for RT-PCR screening. Exclusion Criteria: * Inability to understand the procedures to use the device * Patient participating in an another interventional study * Patient in exclusion period determined by another study * Patient under court protection or guardianship * Patient/trusted person/legal representative/family member for whom it is impossible to give informed information. * Pregnant, parturient or breast-feeding patient
Where it's running
-
CHU de NIMES
Nîmes, France Recruiting -
Université de Nîmes
Nîmes, France Not yet recruiting
Study contacts
- Study coordinator: Valérie COMPAN, PhD
- Email: vcompan@brains4d.com
- Phone: +33664915140
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults
This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.
-
Remdesivir to prevent severe COVID-19 in kidney transplant patients
This study will try giving remdesivir around the time of transplant to see if it prevents severe COVID-19 in adults receiving a kidney transplant who are currently SARS‑CoV‑2 positive with no or mild symptoms.
-
TFH-targeting COVID-19 booster vaccines with and without the 's3' component
This trial will test two experimental COVID-19 booster vaccines — one with an added 's3' component and one without — in healthy adults 40–64 to see if 's3' makes immune responses bigger, broader, and longer-lasting and to check safety.
-
Evaluating Baricitinib for Long COVID Symptoms
This study is testing if the medication baricitinib can help adults with Long COVID feel better physically and mentally compared to a placebo.
-
Study on influenza and COVID-19 effects in pregnant women in India
This study is testing how getting both COVID-19 and influenza affects pregnant women and their babies, while also looking at how vaccinations might help reduce risks during pregnancy.
-
Aerosol box use during cardiopulmonary arrest
This project tests whether using an aerosol box during emergency airway procedures and chest compressions lowers particle spread and is practical for healthcare teams treating cardiac arrest patients, including those with COVID-19.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.